Alistipes

What was studied?

This randomized, double-blind, placebo-controlled trial tested whether daily supplementation with two specific probiotic strains, Bifidobacterium animalis subsp. lactis XLTG11 and Lactiplantibacillus plantarum CCFM8661, could reduce recurrent respiratory tract infections (RRTIs) in children. Over 180 days, the study tracked infection frequency and duration alongside changes in gut microbiota composition, functional metabolic pathways, and immune biomarkers. The design allowed the researchers to link clinical respiratory outcomes to underlying shifts in the gut microbial community and immune regulation.

Who was studied?

The study enrolled 120 children who had been diagnosed with recurrent respiratory tract infections. Participants were randomly assigned to receive either the probiotic combination or a matched placebo daily for 180 days. The abstract does not provide further demographic details such as age range or sex distribution.

What were the most important findings?

Children receiving the probiotics had significantly reduced duration and frequency of fever, cough, upper respiratory tract infections, trachea or bronchitis, pneumonia, and overall RRTI recurrence compared with placebo (all p < 0.05). Gut microbiota profiling at day 180 showed clear community differences between groups, with the probiotic group showing greater abundance of beneficial commensal taxa and the placebo group showing more opportunistic genera. Functional pathway analysis pointed to enhanced metabolic stability in the probiotic recipients, and immune biomarker patterns showed comparatively stable IgG, IgM, and complement C3 levels, suggesting a more regulated humoral immune response. Growth trajectories remained normal in both groups.

What are the greatest implications of this study?

These findings support strain-defined probiotic supplementation as a viable adjunct strategy for reducing the burden of recurrent respiratory infections in children. The parallel shifts in gut microbial composition, metabolic function, and humoral immune stability suggest the respiratory benefit may be mediated through gut-immune axis modulation rather than a direct respiratory-tract effect. Because growth remained normal, the intervention appears well tolerated over a six-month period, supporting its potential for longer-term pediatric preventive use pending further confirmatory trials.

What was studied?

This study examined how diet shapes the human gut microbiome at species-level resolution, using app-based diet logs paired with shotgun metagenomic sequencing. The researchers modeled associations between specific foods, broader dietary patterns (including degree of food processing), and microbial diversity, species composition, and functional pathways. They also tested whether these diet-microbiome associations held up over a multi-year period and explored whether predicted microbiome shifts could inform personalized dietary interventions.

Who was studied?

The analysis drew on 10,068 participants from the Human Phenotype Project, each contributing app-based dietary logs and shotgun metagenomic data. The abstract does not specify demographic details such as age range, sex distribution, or geographic location beyond identifying the cohort as part of this project. This represents one of the largest paired diet-microbiome datasets described in the abstract, but no further population characteristics are given.

What were the most important findings?

Diet significantly predicted microbial diversity, with correlations of 0.26 for richness and 0.24 for the Shannon Index, and it predicted the relative abundance of 669 of 724 species tested (92.4 percent) and 313 of 320 functional pathways (97.8 percent), all at a false discovery rate below 0.05. Feature attribution revealed specific food-microbe links, including coffee with Lawsonibacter asaccharolyticus (r = 0.43), yogurt with Streptococcus thermophilus (r = 0.42), and milk with Bifidobacterium species (r = 0.31 to 0.36). Degree of food processing emerged as a broader dietary pattern predictor of microbial diversity and composition, and 82.5 percent of species showed significant longitudinal tracking between predicted and observed abundances over four years.

What are the greatest implications of this study?

The scale and consistency of these diet-microbiome associations, holding for the large majority of species and pathways tested and persisting over four years, suggest diet is a robust and durable lever for shaping gut microbial ecology. The identification of specific, reproducible food-microbe pairings (such as coffee, yogurt, and milk with particular taxa) and the role of food processing level point toward concrete dietary targets rather than vague nutritional advice. The exploratory framework for simulating personalized dietary interventions with predicted microbiome shift effects moves this work toward practical, individualized nutrition strategies rather than one-size-fits-all recommendations.

What was studied?

This study characterized the gut microbiota of patients with natural killer/T-cell lymphoma (NKTCL), an aggressive malignancy with a poor prognosis, using shotgun metagenomic sequencing. The researchers aimed to identify marker species linked to disease outcomes and to test whether specific gut bacteria could act as probiotics to slow NKTCL progression. They combined cross-sectional microbiota profiling with in vivo and in vitro tumor models, plus metabolomics, RNA sequencing, chromatin immunoprecipitation sequencing, Western blot, immunohistochemistry, and gene knockdown experiments to trace the underlying mechanism.

Who was studied?

The study drew on two Chinese cohorts of NKTCL patients, with findings validated in an independent Korean cohort. Cox proportional hazards models were used to relate microbial marker species to patient survival outcomes across these cohorts. Beyond the human cohorts, the mechanistic work relied on in vivo and in vitro tumor models rather than additional patient populations.

What were the most important findings?

NKTCL patients showed marked gut microbiota dysbiosis, most notably a reduction in Faecalibacterium prausnitzii, a butyrate-producing commensal. This depletion correlated strongly with shorter patient survival. The abstract further indicates that F. prausnitzii demonstrated antitumour properties against NKTCL, with the fuller mechanistic work pointing toward suppression of the JAK-STAT pathway as noted in the study title.

What are the greatest implications of this study?

The findings position F. prausnitzii, a butyrate-producing anti-inflammatory commensal, as a potential prognostic marker and probiotic candidate in NKTCL, a cancer with few therapeutic levers. Restoring this depleted organism could represent a novel adjunct strategy to dampen tumor-promoting JAK-STAT signaling. These results support further investigation into microbiome-targeted interventions for aggressive lymphomas where gut dysbiosis tracks with clinical outcomes.

What was studied?

This study investigated the effects of a novel elite athlete derived probiotic, a multi-strain Lactobacillus consortium, on sleep quality, exercise recovery, and gut microbiome composition. The researchers used a two phase design: an open-label study followed by a controlled longitudinal study. Multi-omics analyses were used to examine changes in microbiome composition and function alongside host physiological markers.

Who was studied?

The study included elite athletes (n = 11), specifically a professional soccer team for the controlled longitudinal phase, and a general population sample (n = 257) in the open-label phase. This dual-cohort design allowed comparison between high-performance athletes and a broader nonathlete population. No further demographic details are given in the abstract.

What were the most important findings?

In the placebo-controlled study, probiotic intervention was associated with significant improvements in self-reported sleep quality (69%), energy levels (31%), and bowel movements (37%) relative to placebo. These improvements coincided with a significant decrease in D-ROMS, a marker of oxidative stress, and a significantly higher free-testosterone to cortisol ratio. Multi-omics analyses revealed specific changes in gut microbiome composition and function that may help explain these host effects.

What are the greatest implications of this study?

The findings suggest that a targeted Lactobacillus consortium can meaningfully influence sleep, energy, recovery-related hormone balance, and oxidative stress through gut microbiome-mediated mechanisms. This supports the gut microbiome as a plausible intervention point connecting sleep and exercise recovery in both elite athletes and the general population. The multi-omics insights point toward mechanistic pathways that could inform future probiotic formulations aimed at recovery and wellness.

What was studied?

This study examined how gut microbiome composition differs across three common diet patterns: omnivore, vegetarian, and vegan. The researchers built metagenomic profiles to determine whether diet pattern leaves a detectable, diet-specific signature in the gut microbiome. They also looked at whether these microbial signatures relate to host cardiometabolic health markers and whether diet-associated gut microbes overlap with microbes found in food itself, including dairy and soil sources.

Who was studied?

The analysis drew on 21,561 individuals pooled from five independent, multinational human cohorts. The abstract does not give further demographic detail (age, sex, or specific countries) for this pooled population. This scale and multinational scope let the researchers test whether diet-microbiome associations held consistently across different populations rather than in a single study group.

What were the most important findings?

Gut microbial profiles distinguished omnivore, vegetarian, and vegan diets with strong accuracy, achieving a mean AUC of 0.85. Red meat intake was a strong driver of the omnivore microbiome signature, with microbes such as Ruminococcus torques, Bilophila wadsworthia, and Alistipes putredinis enriched in omnivores and negatively correlated with cardiometabolic health. In contrast, vegan-associated signature microbes correlated with more favorable cardiometabolic markers and were also found enriched in omnivores who ate more plant-based foods. Diet-specific gut microbes partly overlapped with microbes found in food itself, such as the dairy organism Streptococcus thermophilus and typical soil microbes detected in vegans.

What are the greatest implications of this study?

These diet-associated microbial signatures, including the link between Bilophila wadsworthia and poorer cardiometabolic outcomes in omnivores, suggest gut microbiome profiling could help explain why plant-based diets are associated with better cardiometabolic health. The findings support using microbiome signatures as objective, diet-pattern-specific biomarkers rather than relying solely on self-reported dietary intake. The authors state that these signatures of common Western diet patterns can inform future nutritional interventions and epidemiological research.

What was studied?

Inflammation and innate immune activation are associated with chronic HIV infection, despite effective treatment. Although gut microbiota alterations are linked to systemic inflammation, the relationships between the gut microbiome, inflammation and HIV remain unclear.

Who was studied?

The UPBEAT-CAD sub-study, examining cardiovascular disease (CVD) risk in HIV, enrolled participants matched on HIV status and traditional CVD risk factors. Subclinical CVD was assessed using coronary computed tomography angiography (CCTA). 34 biomarkers were measured using quantitative immunoassays. Microbiota composition was analysed by 16S rRNA sequencing of stool samples, with taxonomic assignment via the SPINGO pipeline. Differentially abundant species were identified by Analysis of Compositions of Microbiomes with Bias Correction (ANCOM-BC) and correlated to biomarkers, diet and CCTA outcomes using Spearman correlation.

What were the most important findings?

Among 81 participants (median age 51 years, 73% male), people with HIV (n=44 , 54%) had a higher prevalence of hypercholesterolaemia (p <0.025) and statin use (p <0.001). A significant separation in gut microbiome β-diversity was observed between people with and without HIV. ANCOM-BC analysis identified 42 differentially abundant species and 10 genera in those with HIV. Enrichment of Bifidobacterium pseudocatenulatum, Megamonas hypermegale and Selenomonas ruminantium and depletion of Fusicatenenibacter correlated with lower plaque burden. Depletion of SCFA-producing Ruminococcus bromii correlated with higher plaque burden and fat intake, while depletion of Bacteroides spp and Alistepes spp correlated with elevated inflammatory biomarkers (D-dimer, CD40-ligand, CRP and IFN-γ).

What are the greatest implications of this study?

Significant gut microbiota differences in people with HIV were linked to subclinical CVD, diet, and inflammation, suggesting a role for the microbiome in cardiovascular risk in HIV infection.

What was studied?

This study profiled the fecal virome, bacteriome, and blood metabolome together in schizophrenia, testing whether gut viruses (mainly bacteriophages) shape the disease-associated bacterial community and whether those shifts reach the host through circulating metabolites.

Who was studied?

Forty-nine first-episode schizophrenia patients, most drug-naive or treated for fewer than five days, and 49 age-, sex-, and BMI-matched healthy controls at West China Hospital, Sichuan University (2021 to 2022). Fecal shotgun sequencing covered 95 participants and untargeted plasma metabolomics 92, with age, sex, BMI, and medication days controlled.

What were the most important findings?

Bacterial beta-diversity separated patients from controls at the family, genus, and species levels while alpha-diversity did not differ, and combining MaAsLin2 with ANCOM-BC flagged 7, 14, and 45 differentially abundant taxa respectively. The healthy viral-bacterial transkingdom correlation network was largely lost in schizophrenia, and the co-occurring metabolites were enriched in bile-acid and eicosanoid pathways linked to inflammation. A serial-mediation model supported a gut viruses to bacteria to metabolites to schizophrenia chain, with metabolites carrying most of the indirect effect.

What are the greatest implications of this study?

The results frame schizophrenia-associated dysbiosis as a virome-bacteriome-metabolome system rather than a bacterial shift alone, and highlight bile-acid and eicosanoid (COX and prostaglandin) metabolism as microbiota-linked, potentially treatable inflammatory routes. As a small cross-sectional study, it establishes associations and candidate biomarkers, not causation.

What was studied?

Excess amino acids from a protein-rich diet are mainly catabolized in the liver. However, it is still unclear to what extent the gut microbiota may be involved in the mechanisms governing this catabolism. Therefore, the aim of this study was to investigate whether consumption of different dietary protein concentrations induces changes in the taxonomy of the gut microbiota, which may contribute to the regulation of hepatic amino acid catabolism. Consumption of a high-protein diet caused overexpression of HIF-1α in the colon and increase in mitochondrial activity, creating a more anaerobic environment that was associated with changes in the taxonomy of the gut microbiota promoting an increase in the synthesis of secondary bile acids, increased secretion of pancreatic glucagon. This effect was demonstrated in pancreatic islets, where secondary bile acids stimulated the expression of the PC2 enzyme that promotes glucagon formation. The increase in circulating glucagon was associated with an induction of the expression of hepatic amino acid-degrading enzymes, an effect attenuated by antibiotics. Thus, high protein intake in mice and humans induced the increase of different species in the gut microbiota with the capacity to produce secondary bile acids leading to an increase in secondary bile acids and glucagon levels, promoting amino acid catabolism.

What was studied?

The gut microbiota has been linked to non-communicable diseases, including chronic kidney disease (CKD). However, the relationships between gut microbiome composition changes, uraemic toxins (UTs) accumulation, and diet on CKD severity and progression remain underexplored. To characterise relationships between gut microbiome composition and functionality, UTs diet, and CKD severity and progression, as well as assess microbial contributions to UTs accumulation through mice faecal microbiota transplantation (FMT).

Who was studied?

This study profiled the gut microbiome of 240 non-dialysis patients with CKD (CKD-REIN cohort) using shotgun metagenomics, with follow-up in 103 patients after 3 years, with comparisons with healthy volunteers from the Milieu Intérieur cohort. A multiomics approach identifies features associated with CKD severity (and progression), with validation in an independent Belgian cohort. Experimental models used FMT to test CKD gut microbiome effects on UTs and kidney fibrosis. Changes in gut microbiome over time were evaluated, and the impact of diet on these changes was assessed.

What were the most important findings?

Compared with matched healthy controls, patients with CKD exhibited gut microbiota alteration, with enrichment of UT precursor-producing species. Patients with severe CKD exhibited higher UT levels and greater enrichment of UT (precursor)-producing species in the microbiota than patients with moderate CKD. Over time, UT (precursor)-producing species increased, and a plant-based low protein diet appeared to mitigate these changes. FMT from patients with CKD to antibiotic-treated CKD model mice increased serum UT levels and exacerbated kidney fibrosis.

What are the greatest implications of this study?

This study highlights the role of the microbiome and UTs in CKD, suggesting a potential therapeutic target to slow disease progression.

What was studied?

Metabolic syndrome (MS) and type 2 diabetes (T2D) are metabolically related diseases with rising global prevalence and increasingly evident links to the intestinal microbiota. Research suggests that imbalances in microbiota composition may play a crucial role in their pathogenesis. Specific population cohorts, such as the one in Galicia, Spain, offer the opportunity to analyze microbiota patterns within a distinct geographical and genetic context. This study was performed to investigate the relationship between the intestinal microbiota and MS and T2D.

Who was studied?

A cohort of 79 volunteers was analyzed over a 2-year study period. Recruitment posed significant challenges because of strict inclusion criteria (918PTE0540; PCI2018-093284), which required participants to be free from chronic medications and have a moderate to high risk of developing T2D. Volunteers were classified based on their serum glucose levels, body mass index, and the presence or absence of MS. To analyze the microbiota composition, amplicon sequencing of 16S rRNA genes was performed on stool samples. Alpha diversity was assessed using the Chao and Shannon indices, while beta diversity was evaluated using permutational analysis of variance with Bray-Curtis and Chao distances. Differential abundance analysis was conducted using the LinDA method.

What were the most important findings?

In patients with MS, we observed a higher Firmicutes/Bacteroidetes ratio and an increased prevalence of Blautia compared to healthy patients. than in healthy individuals. Other enriched taxa in patients with MS included Tyzerella, Streptococcus, and Ruminococcus callidus. In patients with T2D, we observed a higher Bacteroidetes/Firmicutes ratio and a decrease in the phylum Actinobacteria compared with healthy individuals. Taxa such as Dorea, Prevotella, Dialister invisus, Fusicatenibacter, and Coprococcus were associated with T2D, while beneficial taxa such as Eubacterium, Ligilactobacillus, and Acidaminococcus were more prevalent in healthy or prediabetic individuals.

What are the greatest implications of this study?

This study reveals notable differences in the intestinal microbiota composition among patients with MS and T2D. Changes in microbial composition, particularly the Firmicutes/Bacteroidetes ratio, may serve as indicators of underlying pathology. At more specific taxonomic levels, several enriched taxa were identified in patients with MS, including Blautia, Tyzzerella, Dorea, Streptococcus, and Ruminococcus callidus. Additionally, species such as Dorea longicatena and Dialister invisus were enriched in prediabetic and diabetic patients, whereas beneficial genera (Eubacterium, Acidaminococcus, Bifidobacterium, and Ligilactobacillus) were more prevalent in healthy and prediabetic individuals than in those with T2D.

What was studied?

This study examined whether rifaximin, a gut-specific non-absorbable antibiotic, could reduce gut-derived systemic inflammation in severe acute pancreatitis (SAP). The researchers combined murine experimental models with a single-center, open-label randomized controlled trial (ChiCTR2100049794). They assessed pancreatic injury, systemic inflammatory markers, and gut microbiota composition, and tested whether rifaximin's effects depended on modulating the microbiota by using antibiotic-treated and germ-free mice.

Who was studied?

The animal component used murine models of severe acute pancreatitis, including antibiotic-treated and germ-free mice used to probe the mechanism. The clinical component enrolled 60 patients with predicted severe acute pancreatitis, randomized to receive rifaximin or standard control treatment. No further demographic details are given in the abstract.

What were the most important findings?

In mice, rifaximin reduced pancreatic injury and systemic inflammation and decreased mucin-degrading gut genera such as Akkermansia, but its protective effects persisted even in antibiotic-treated and germ-free mice, indicating mechanisms beyond microbiota modulation. In patients, rifaximin significantly lowered systemic inflammation, with white blood cell count falling from a median of 11.50 x10^9/L to 8.49 x10^9/L and TNF-alpha falling from 15.05 pg/mL to 11.00 pg/mL. However, the rate of culture-confirmed infection was identical between rifaximin and control groups (13.3% vs 13.3%), and adverse events were comparable between groups.

What are the greatest implications of this study?

The findings suggest rifaximin can dampen systemic inflammation in severe acute pancreatitis through mechanisms that are not solely dependent on reshaping the gut microbiota, pointing to a possible direct anti-inflammatory or barrier-protective effect. Because inflammation markers improved without any change in infection risk, rifaximin may offer a safe adjunct for controlling inflammatory injury in SAP without added infectious risk. This supports further investigation of rifaximin as a therapeutic strategy for gut-derived inflammation in acute pancreatitis, alongside continued study of its non-microbiota-dependent mechanisms.

What was studied?

Colorectal cancer (CRC) is a significant global health burden, ranking amongst the top causes of cancer-associated mortality. Emerging evidences implicate gut microbiota as a prominent mediator of cell signalling, immune, and metabolic pathways in the pathophysiology of CRC.

Who was studied?

We analysed 16S rRNA amplicon sequencing data (PRJEB7774) from faecal samples of 46 CRC patients and 63 healthy controls to assess shifts in microbial composition, diversity, and biomarker taxa. Differential abundances of microbiota were determined using Linear Discriminant Analysis Effect Size (LEfSe) and Random Forest (RF) models. Host-microbiota interactions were explored using the Human Microbiome Affect the Host Epigenome (MIAOME) and Host Genetic and Immune Factors Shaping Human Microbiota (GIMICA) databases, with key host genes validated using Gene Expression Profiling Interactive Analysis (GEPIA) and The Cancer Genome Atlas (TCGA) datasets. Functional enrichment analyses were performed to uncover associated biological processes and pathways.

What were the most important findings?

CRC samples exhibited significantly reduced alpha diversity and distinct beta diversity profiles, compared to controls. Taxonomic profiling revealed an enrichment of potentially pathogenic bacteria, including Prevotella copri, Methanobrevibacter smithii, Bacteroides eggerthii, and Dialister invisus, and depletion of beneficial microbes such as Bifidobacterium animalis and Ruminococcus sp. Predicted host-microbe interactions highlighted associations between key microbial biomarkers and inflammation-related genes (CD44, CXCL8, DUSP16, FOXP3, IFNGR2, IL18), all significantly overexpressed in CRC samples. Enrichment analyses linked these genes to immune pathways, including NF-κB, TLR and cytokine signalling.

What are the greatest implications of this study?

Our study reveals a distinct gut microbiota signature in CRC and suggests functional interactions between microbial dysbiosis and host inflammatory responses. These findings emphasize the potential of microbiota-based interventions and microbial metabolites as adjunctive strategies for the management of CRC.

What was studied?

This study examined the tracheal and cecal microbiome composition across three broiler chicken genotypes including a heritage New Hampshire × Columbian cross (NHC) and modern Ross × Ross 308 (R308) and Ross YP × Ross 708 (R708) broilers, using full-length 16S rRNA sequencing. Birds were reared in floor pens, and at 56 d of age, cecal and tracheal samples were collected from 8 birds per genotype and subjected to DNA extraction followed by PCR amplification of full-length 16S rRNA. Obtained amplified PCR product was sequenced using MinION. A total of 1.8 million reads for tracheal samples and 1.2 million reads for ceca samples were obtained from 24 birds. Despite similar alpha diversity matrixes (Shannon, Simpson, Pielou's evenness, and Chao1) across genotypes in both tracheal and cecal samples, beta diversity analysis revealed significant differences in community composition. Tracheal and cecal microbiota varied significantly among genotypes, particularly NHC with the R308 and R708 groups. At the phylum level, Bacillota (Firmicutes) dominated both tracheal and cecal samples across genotypes. In the trachea, NHC and R708 birds exhibited high relative abundance of Enterococcus cecorum, while Jeotgalicoccus meleagridis dominated R308. Differential abundance analysis showed higher abundance of potentially beneficial bacteria such as Limosilactobacillus pontis and Aerococcus viridans in R308 and R708, while NHC birds had higher levels of species like Merdibacter massiliensis and Agathobaculum butyriciproducens. Cecal microbiome analysis revealed genotype-specific enrichment of species, with NHC birds showing higher abundance of potential pathogens like Shigella boydii and Escherichia fergusonii compared to R708. In contrast, R308 birds harboured more potentially beneficial taxa, including Lactobacillus acidophilus and Limosilactobacillus vaginalis, compared to R708. Pairwise comparisons further highlighted Intestinibacter bartlettii and other potentially beneficial microbes being significantly enriched in R308 over R708. Overall, while microbial richness remained consistent, significant genotype-associated differences in bacterial community structure and genotype-specific microbial abundance were observed, emphasizing the influence of host genetics on microbiota composition and potential implications for poultry health and performance.

What was studied?

This study used species-level shotgun metagenomic sequencing to characterize the gut microbiota of men who have sex with men (MSM). It investigated why the MSM gut microbiome, previously shown to differ from that of non-MSM, so often resembles the microbial communities seen in non-Westernized populations. The researchers also used questionnaire data and machine learning to link specific sexual practices to variation in microbiota composition among MSM.

Who was studied?

The study population was men who have sex with men of Western origin, compared against patterns typical of non-Westernized populations. The abstract does not give an exact sample size, but participants contributed both stool samples for shotgun metagenomics and questionnaire responses on sexual practices. This design allowed the authors to relate individual behavioral data to individual gut microbiome profiles within the MSM cohort.

What were the most important findings?

Many MSM with Western origin had gut microbiomes resembling those of non-Westernized populations rather than typical Western gut profiles. These microbiomes were frequently dominated by Prevotellaceae family members, including co-colonization by species from the Segatella copri complex alongside unknown Prevotellaceae members. Questionnaire analysis and machine learning further identified specific sexual practices as microbial features associated with this altered, Prevotellaceae-rich composition.

What are the greatest implications of this study?

The findings show that sexual activity itself can be a driver of major gut microbiome alterations, independent of the diet and lifestyle factors usually invoked to explain Westernized versus non-Westernized microbiota differences. Because MSM gut microbiomes can resemble non-Westernized profiles, sexual practice becomes an important variable that population-based microbiota studies may need to account for. This has implications for how researchers select and interpret control or reference populations in microbiome research and for disentangling behavioral from dietary or geographic influences on gut microbial composition.

What was studied?

This study examined the relationship between the gut microbiome and the host genome and transcriptome in colorectal cancer (CRC). Researchers profiled the fecal microbiome structure alongside genomic and transcriptomic data from matched tumor and normal mucosa tissue. Exome sequencing was used to identify somatic mutations, and gene expression patterns were annotated and clustered against microbial abundance data. Immune and stromal cell composition was also estimated from the transcriptomic profiles.

Who was studied?

The cohort consisted of 41 patients with colorectal cancer. For each patient, matched tumor tissue and normal mucosa tissue were analyzed alongside fecal microbiome samples. The abstract does not provide further demographic details such as age, sex, or geographic origin of the participants.

What were the most important findings?

The researchers identified 22 gut microbial species significantly associated with CRC and estimated relative abundance across functional (KEGG) pathway categories. Four significantly mutated genes, TP53, APC, KRAS, and SMAD4, were linked to specific cancer-associated microbes. Fusobacterium nucleatum in particular showed a positive correlation with multiple host metabolic pathways, tying a specific pathogen to altered tumor metabolism. The abstract text is truncated before further results are described.

What are the greatest implications of this study?

The findings support a functional link between specific gut bacteria, such as Fusobacterium nucleatum, and the somatic mutation landscape and metabolic activity of colorectal tumors. This multi-omic approach suggests that microbial taxa may interact with host driver mutations like TP53, APC, KRAS, and SMAD4 rather than merely coexisting with the tumor. Such associations could inform future work on microbiome-informed risk stratification or targets in CRC, though the abstract does not describe therapeutic testing or outcomes.

Who was studied?

We used deep sequencing of fecal samples from 23 treatment-naive TB patients and 48 healthy donors to reconstruct the gut microbiome's metabolic capacity and strain/species-level content.

What were the most important findings?

We show that the systematic depletion of the commensal flora of the large intestine, Bacteroidetes, and an increase in Actinobacteria, Firmicutes, and Proteobacteria such as Streptococcaceae, Erysipelotrichaceae, Lachnospiraceae, and Enterobacteriaceae explains the strong taxonomic divergence of the gut community in TB patients. The cumulative expansion of diverse disease-associated pathobionts in patients reached 1/4 of the total gut microbiota, suggesting a heavy toll on host immunity along with MTB infection. Reconstruction of metabolic pathways showed that the microbial community in patients shifted toward rapid growth using glycolysis and excess fermentation to produce acetate and lactate. Higher glucose availability in the intestine likely drives fermentation to lactate and growth, causing acidosis and endotoxemia.

What was studied?

The study examined how peripheral neurons connected to the gastrointestinal tract influence the gut microbiome and gut physiology. Researchers activated choline acetyltransferase (ChAT)-expressing or tyrosine hydroxylase (TH)-expressing gut-associated neurons in mice. They then measured effects on intestinal microbial communities, microbial metabolites (including bile acid profiles), and host physiological responses using multi-omics approaches.

Who was studied?

The subjects were mice in which ChAT+ or TH+ gut-associated neurons were experimentally activated. The abstract does not give a specific sample size or strain detail, so no cohort numbers can be stated. This was an animal model study, not a human cohort, and it generated multi-omics datasets from these mice rather than drawing on a public metagenomic dataset.

What were the most important findings?

Activating either ChAT+ or TH+ neurons reshaped the structure of the intestinal microbiome, including changes to bile acid profiles and fungal colonization. Physiologically, activation of either neuron type increased fecal output, showing a shared downstream effect on gut transit. Only ChAT+ neuron activation additionally increased colonic contractility and produced diarrhea-like fluid secretion, indicating that these two neuronal subtypes act through distinct physiological pathways despite some overlapping effects.

What are the greatest implications of this study?

The findings show that distinct subsets of peripheral, gut-associated neurons can independently shape microbiome composition and gastrointestinal physiology without requiring signals from the brain. This suggests the enteric and peripheral nervous system directly sculpts microbial ecology, including bacterial and fungal populations and bile acid metabolism, rather than the microbiome being shaped only by diet or host genetics. Because different neuron subtypes produce different physiological outcomes (fecal output alone versus contractility and diarrhea-like secretion), this points to neuron-specific pathways as potential targets for understanding or treating GI motility and secretory disorders.

What was studied?

This study tested whether Parkinson's disease alters the periodontitis-associated oral microbiome. Researchers collected unstimulated saliva samples and stool samples and profiled microbial communities using next-generation sequencing of the 16S ribosomal RNA gene (V1-V3 regions). Clinical, periodontal, and neurological parameters were recorded, including the severity of Parkinson's disease motor dysfunction.

Who was studied?

Three groups were enrolled: patients with periodontitis and Parkinson's disease (PA+P), patients with periodontitis but without Parkinson's disease (P), and systemically and periodontally healthy individuals used as controls (HC). The abstract does not give exact group sizes. The PA+P group had mild to moderate motor dysfunction, and plaque scores were comparable between the PA+P and P groups, indicating similarly effective oral hygiene.

What were the most important findings?

Beta diversity in saliva differed significantly between HC and PA+P, between HC and P, and between P and PA+P groups, showing that both periodontitis and the presence of Parkinson's disease reshape the oral microbial community. Saliva and fecal microbial profiles were distinct from each other. Mycoplasma faucium, Tannerella forsythia, Parvimonas micra, and Saccharibacteria (TM7) were increased in the P group, while Prevotella pallens, Prevotella melaninogenica, and Neisseria multispecies were more abundant in the PA+P group. In fecal samples from the P group, Ruthenibacterium lactatiformans, Dialister succinatiphilus, Butyrivibrio crossotus, and Alloprevotella tannerae were detected.

What are the greatest implications of this study?

The findings support the hypothesis that Parkinson's disease is associated with a distinct periodontitis-related oral microbial signature, separate from periodontitis alone. Because oral and gut microbial profiles diverged between groups despite similar oral hygiene, the results suggest disease-associated shifts rather than simple hygiene differences drive these community changes. This points to the oral-gut microbiome axis as a potential area for further investigation in Parkinson's disease and periodontitis.

What was studied?

This study examined the early development of the human gut microbiome by comparing infants to their mothers and grandmothers within the same family lines. Researchers used a multi-omics approach combining metagenomics (16S rRNA gene and shotgun sequencing) with two independent metabolomics platforms, gas chromatography and capillary electrophoresis coupled to mass spectrometry. The goal was to characterize differences in microbial populations, function, and metabolite output across three generations.

Who was studied?

Fecal samples were collected from 200 individuals spanning three generations of the same families. This included infants aged 0 to 12 months (55% female, 45% male) along with their respective mothers and grandmothers. The design allowed direct comparison of gut microbiota and metabolome across a shared generational line.

What were the most important findings?

Infants showed markedly less diverse gut microbiota than their mothers and grandmothers, along with distinct microbial population and functional profiles. The infant metabolome also differed substantially from the adults, particularly in short- and branched-chain fatty acids. These metabolite shifts were linked to corresponding differences in bacterial populations between infants and elders.

What are the greatest implications of this study?

The findings offer biochemical insight into how the gut microbiome is shaped during infancy within a single family lineage. Because dysregulation of the gut microbiome at this early stage may contribute to disease later in life, understanding these generational differences could inform strategies to support healthy microbiome development in infants. The authors suggest this multi-omics approach could ultimately help improve childhood health outcomes.

What was studied?

This study examined gut microbial features associated with Parkinson's disease (PD) by meta-analyzing shotgun metagenomic sequencing data across six independent datasets from different countries. The researchers also established GC-MS and LC-MS/MS assays to directly quantify fecal short-chain fatty acids (SCFAs) and fecal polyamines. They analyzed taxonomic composition, functional gene pathways, and carbohydrate-active enzymes (CAZymes) in relation to PD status, adjusting for confounding factors.

Who was studied?

The core dataset consisted of 94 PD patients and 73 controls whose fecal samples were shotgun sequenced in Japan. This Japanese cohort was combined with five previously reported datasets from the USA, Germany, China (two separate cohorts), and Taiwan. In total, the meta-analysis spanned six countries, giving the study an international, multi-cohort scope rather than a single-population sample.

What were the most important findings?

Across all six datasets, alpha-diversity was consistently increased in PD. Taxonomic analysis showed Akkermansia muciniphila was increased in PD, while Roseburia intestinalis and Faecalibacterium prausnitzii, both associated with anti-inflammatory, butyrate-related commensal activity, were decreased. Genes for riboflavin and biotin biosynthesis and five of six CAZyme categories were markedly decreased in PD, and fecal SCFAs and polyamines were significantly reduced, with riboflavin/biotin gene abundance positively correlated with these metabolite levels.

What are the greatest implications of this study?

The convergent, cross-country decrease in Faecalibacterium prausnitzii, Roseburia intestinalis, SCFAs, and polyamines suggests a reproducible loss of beneficial, anti-inflammatory commensal function in PD gut microbiota. Because the specific bacteria driving reduced riboflavin biosynthesis differed between Japan/USA/Germany and China1/China2/Taiwan, the findings imply that shared functional deficits in PD can arise from different taxonomic routes depending on population. This points toward B-vitamin biosynthesis and short-chain fatty acid/polyamine metabolism as potential functional biomarkers or intervention targets for PD that generalize better across populations than single-taxon signatures.

What was studied?

This study examined the relationship among urinary phthalate (PAE) metabolites, gut microbiota composition, and gut metabolome profiles in dementia with Lewy bodies (DLB). Researchers measured urinary phthalate metabolite levels using liquid chromatography and profiled gut microbiota and metabolites using high-throughput sequencing and liquid chromatography-mass spectrometry. They then used a fecal microbiota transplantation (FMT) experiment in alpha-synuclein transgenic DLB/Parkinson's disease mice to test whether phthalate-associated gut dysbiosis could contribute to worsening cognitive dysfunction.

Who was studied?

The human portion of the study included 43 patients with dementia with Lewy bodies and 45 normal control subjects, whose urine and fecal samples were analyzed. The animal portion used alpha-synuclein transgenic mice modeling DLB/Parkinson's disease, which received fecal microbiota transplants to test causal effects of gut dysbiosis on cognition.

What were the most important findings?

DLB patients had higher levels of several phthalate metabolites, including DEHP metabolites MEOHP, MEHHP, and MEHP, as well as MMP and MnBP, but lower levels of MBP and MBzP compared to controls. Gut microbiota composition also differed between groups, with a significantly higher abundance of Ruminococcus gnavus and a lower abundance of Prevotella in DLB patients. The FMT experiment was performed to verify whether phthalate-associated gut dysbiosis contributes to aggravating cognitive dysfunction in the DLB/PD mouse model.

What are the greatest implications of this study?

These findings suggest that environmental phthalate exposure is associated with distinct patterns of urinary metabolites and gut dysbiosis in people with dementia with Lewy bodies. The use of an FMT model linking phthalate-associated dysbiosis to cognitive dysfunction raises the possibility that environmental chemical exposures could influence neurodegenerative disease risk through gut microbiota changes. This points to gut microbiota and metabolome profiling as a potential avenue for understanding environmental contributions to DLB and warrants further mechanistic investigation.

What was studied?

This study examined the gut microbiome's association with type 2 diabetes (T2D) by analyzing shotgun metagenomic sequencing data. Researchers looked beyond species-level associations to strain-level and phylogenetic diversity within species, aiming to identify specific microbial features and functional pathways linked to T2D. The analysis also explored community-level functional changes, such as perturbations in glucose metabolism, and mechanisms like horizontal gene transfer that could explain strain-specific effects on metabolic risk.

Who was studied?

The study drew on 8,117 shotgun metagenomes pooled from 10 cohorts spanning the United States, Europe, Israel, and China. These cohorts included individuals with type 2 diabetes, prediabetes, and normoglycemic (non-diabetic) status. The abstract does not provide individual-level demographic details, but the analysis represents a large, multi-national, cross-cohort metagenomic dataset.

What were the most important findings?

Dysbiosis in 19 phylogenetically diverse species was associated with T2D at a false discovery rate below 0.10, including enrichment of Clostridium bolteae and depletion of Butyrivibrio crossotus. These microorganisms contributed to community-level functional changes, such as perturbations in glucose metabolism, that may underlie T2D pathogenesis. The study further identified within-species phylogenetic diversity across 27 species, such as Eubacterium rectale, that explained inter-individual differences in T2D risk, with some effects attributable to strain-specific gene carriage involved in horizontal gene transfer and other novel biological processes.

What are the greatest implications of this study?

By resolving microbial associations with T2D down to the strain level, this work helps explain why prior species-level findings have been inconsistent across studies. Identifying strain-specific gene carriage and functional pathways, including those affecting glucose metabolism, offers a clearer mechanistic basis for how gut microbes may contribute to T2D pathogenesis. This strain-resolved approach could inform future efforts to develop microbiome-based biomarkers or targeted interventions for metabolic disease risk.

What was studied?

The aim of this study was to assess the correlation between gut microbial taxonomy and various ovarian responses to controlled ovarian stimulation. A total of 22 IVF cycles with a follicle-to-oocyte index (FOI) < 0.5 and 25 IVF cycles with FOI ≥ 0.5 were included in this study. Baseline demographic characteristics were compared between the two groups. Metagenomic sequencing was performed to analyze fecal microbial community profiles. Mice were used to evaluate the effect of Bifidobacterium_longum on ovarian response to stimulation. Compared with FOI < 0.5 group, women in group with FOI ≥ 0.5 had significant more oocytes retrieved (p < 0.01). Prevotella_copri, Bateroides_vulgatus, Escherichia_coli and Bateroides_stercoris were more abundant in FOI < 0.5 group while Bifidobacterium_longum, Faecalibacterium_prausnitzii, Ruminococcus_gnavus and Bifidobacterium_pseudocatenula were more abundant in FOI ≥ 0.5 group. After adjusting for women's age and BMI, Pearson correlation analysis indicated alteration of gut microbiome was related with serum E2, FSH, number of oocytes retrieved and clinical pregnancy rate. Animal study showed ovarian response will be improved after Bifidobacterium_longum applied. An increased abundance of Bacteroidetes and Prevotella copri, as well as a decreased abundance of Bifidobacterium longum, have been found to be associated with poor ovarian responsiveness. Changes in gut microbiomes have been observed to be correlated with certain clinical characteristics. The potential enhancement of ovarian response may be facilitated by the integration of Bifidobacterium longum.

What was studied?

This study examined how environmental, socioeconomic, and health factors relate to gut microbiome composition at both the species and strain level. Researchers used deeply sequenced metagenomic data to identify associations between bacterial species and a range of host phenotypes and situational factors. They also performed a meta-analysis of species-level profiles across multiple datasets to look for consistent patterns, such as links to body mass index.

Who was studied?

The study drew on a community-based cohort of 1,871 people living in 19 isolated villages in the Mesoamerican highlands of western Honduras. This is a non-industrialized, geographically isolated population, a setting the authors note remains uncommon in deep gut microbiome sequencing studies. Additional comparisons were made using species-level profiles from other, unspecified datasets as part of a meta-analysis.

What were the most important findings?

Socioeconomic factors accounted for 51.44% of all associations found between the gut microbiome and human phenotypes, making them the dominant category of influence. Meta-analysis across datasets identified several bacterial species associated with body mass index, consistent with prior research. Incorporating strain-level phylogenetic information changed the overall picture of host-microbiome relationships, especially for factors like household wealth, where wealthier individuals were found to harbor different strains of Eubacterium rectale than less wealthy individuals.

What are the greatest implications of this study?

The findings suggest that socioeconomic circumstances are a major driver of gut microbiome variation, potentially more so than many other individual health factors. The demonstration that strain-level differences (not just species presence) track with wealth indicates that species-level analysis alone can miss biologically meaningful variation. The authors conclude that gut microbiome surveillance in such populations could help illuminate broader patterns relevant to both individual and public health.

What was studied?

This study examined whether fecal microbiota transplantation (FMT) changes gut microbiota composition and function in patients with irritable bowel syndrome (IBS), and whether those changes relate to symptom improvement. The researchers used 16S rRNA gene amplicon sequencing and shotgun metagenomics to track microbiota shifts after FMT. The study was part of a randomized, placebo controlled FMT trial, allowing comparison between active treatment and placebo. It specifically probed prior inconsistent findings on the link between post-FMT microbiota change and clinical outcome.

Who was studied?

The study population consisted of 49 IBS patients enrolled in a randomized, placebo controlled FMT trial. Patients received either FMT from a healthy donor or a placebo procedure. Fecal samples from these patients were analyzed for microbiota composition and function before and after treatment. The abstract does not specify additional demographic details such as age range or sex distribution.

What were the most important findings?

FMT from a healthy donor successfully modulated microbiota composition and functional profiles in IBS patients, confirming the transplant altered the gut ecosystem as intended. However, this successful microbiota modulation was not associated with resolution of IBS symptoms. Notably, a donor derived strain of Prevotella copri came to dominate the microbiota specifically in FMT group patients who had low relative abundance of P. copri before treatment. This suggests that a recipient's pre-existing microbiota state influences how well donor strains colonize.

What are the greatest implications of this study?

The findings indicate that changing gut microbiota composition through FMT is not sufficient on its own to relieve IBS symptoms, pointing to a disconnect between microbial engraftment and clinical benefit. This highlights the multifactorial nature of IBS, meaning symptoms likely depend on more than microbiota composition alone. The study also shows that a recipient's baseline microbiota, such as pre-FMT Prevotella copri levels, shapes whether donor strains successfully colonize. These results suggest future FMT research should look beyond simple compositional shifts to understand what actually drives symptom relief in IBS.

What was studied?

This study examined how exclusive enteral nutrition (EEN), a first-line therapy for pediatric Crohn's disease, produces its protective effects on the gut. The researchers used integrated multi-omics analysis of fecal microbiota and metabolites to identify functional network clusters associated with treatment response. They further validated these diet-driven microbiome changes using gut chemostat cultures and by transferring microbiota into germ-free Il10-deficient mice.

Who was studied?

The abstract describes a prospective pediatric cohort of treatment-naive Crohn's disease patients, registered as German Clinical Trials DRKS00013306, who were followed as they began EEN therapy. Exact patient numbers are not given in the abstract. Findings from this human cohort were then extended experimentally using gnotobiotic (germ-free) Il10-deficient mice colonized with patient-derived microbiota.

What were the most important findings?

Multi-omics analysis identified individually variable microbiome network clusters, with Lachnospiraceae and medium-chain fatty acids emerging as protective features associated with EEN response. Bioorthogonal non-canonical amino acid tagging pinpointed specific bacterial species that responded to medium-chain fatty acids, and metagenomic analysis revealed high strain-level dynamics during EEN therapy. When patient-derived microbiota were transferred into gnotobiotic Il10-deficient mice, individual patient-specific strain signatures could either prevent or cause inflammatory bowel disease-like inflammation.

What are the greatest implications of this study?

The findings show that EEN operates through explicit, functional, and highly individualized changes in the fecal microbiome rather than a single uniform mechanism. Because protective effects were tied to specific strains and metabolites such as medium-chain fatty acids, this suggests that microbiome and metabolite profiling could help predict or enhance EEN response in pediatric Crohn's disease. The demonstration that individual strain signatures can causally prevent or induce inflammation in a gnotobiotic model also supports strain-level and metabolite-targeted approaches as a path toward more precise dietary or microbial therapies for Crohn's disease.

What was studied?

This study examined the fecal microbiota of Korean patients with inflammatory bowel disease (IBD) to characterize how bacterial composition relates to clinical phenotypes. Researchers compared ulcerative colitis (UC), Crohn's disease (CD), and healthy controls using 16S sequencing of fecal samples. They analyzed alpha-diversity and overall community composition using the EzBioCloud database and 16S microbiome pipeline. The goal was to identify taxonomic biomarkers useful for diagnosis and prognosis in IBD.

Who was studied?

The study included 70 patients with ulcerative colitis, 39 patients with Crohn's disease, and 100 healthy control individuals, all from a Korean population. Fecal samples were collected from each group and amplified via polymerase chain reaction before sequencing on the Illumina MiSeq platform. Within the UC group, patients were further stratified by disease severity and disease extent for additional analysis.

What were the most important findings?

Alpha-diversity of fecal bacteria was significantly lower in both UC and CD patients compared to healthy controls. Bacterial community composition, measured via Bray-Curtis dissimilarities, differed significantly between UC, CD, and healthy controls, and also differed between UC and CD themselves. Within UC, diversity decreased further as disease severity and extent increased, with community composition also varying by disease extent. The researchers identified 9 biomarkers of UC severity, 6 biomarkers of disease extent, 5 biomarkers of active disease, and additional biomarkers described in the abstract as being identified for disease course or prognosis.

What are the greatest implications of this study?

These findings support the fecal microbiota as a potential tool for distinguishing UC and CD from healthy individuals and from each other in a Korean population. The identification of taxa linked to severity, extent, and disease activity suggests fecal bacterial profiling could aid in staging and monitoring IBD. This points toward a role for microbiome-based biomarkers in personalizing diagnostic and prognostic assessment for IBD patients, pending further validation in additional cohorts.

What was studied?

This study investigated the microbiome associated with ovarian cancer (OC) and its potential role in detection, disease progression, and prognosis. Researchers examined microbial taxa across multiple body sites in OC patients compared with a benign cohort. The aim was to identify microbial indicators that could aid early detection, track disease stage and grade, and predict treatment response.

Who was studied?

The abstract does not give a specific cohort size or demographic description. It describes an OC patient cohort compared against a benign cohort, with sampling across several body sites; stool and omentum were sampled in the OC cohort but not in the benign cohort. Beyond this, the population can only be described in general terms as ovarian cancer patients versus patients with benign gynecological conditions.

What were the most important findings?

The researchers identified a distinct OC microbiome with general enrichment of several microbial taxa, including Dialister, Corynebacterium, Prevotella, and Peptoniphilus, across body sites in the OC cohort. These same taxa were depleted in advanced-stage and high-grade OC patients compared with early-stage and low-grade patients, suggesting decreased accumulation as disease advances. The mainly pathogenic taxa were also more abundant in OC patients with adverse treatment outcomes compared to those without treatment-related events.

What are the greatest implications of this study?

The enrichment and depletion patterns of these taxa suggest they could serve as potential indicators for early detection of ovarian cancer. Their accumulation in patients with adverse treatment outcomes suggests they could also help predict how patients will respond to treatment. Together these findings point to a possible diagnostic and prognostic role for the OC-associated microbiome, though the abstract does not describe validation in an independent cohort.

What was studied?

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease. Increasing evidence indicates that the gut microbiota can play an important role in the pathophysiology of NAFLD. Recently, several studies have tested the predictive value of gut microbiome profiles in NAFLD progression; however, comparisons of microbial signatures in NAFLD or non-alcoholic steatohepatitis (NASH) have produced discrepant results, possibly due to ethnic and environmental factors. Thus, we aimed to characterize the gut metagenome composition of patients with fatty liver disease.

Who was studied?

Gut microbiome of 45 well-characterized patients with obesity and biopsy-proven NAFLD was evaluated using shot-gun sequencing: 11 non-alcoholic fatty liver controls (non-NAFL), 11 with fatty liver, and 23 with NASH.

What were the most important findings?

Our study showed that Parabacteroides distasonis and Alistipes putredenis were enriched in fatty liver but not in NASH patients. Notably, in a hierarchical clustering analysis, microbial profiles were differentially distributed among groups, and membership to a Prevotella copri dominant cluster was associated with a greater risk of developing NASH. Functional analyses showed that although no differences in LPS biosynthesis pathways were observed, Prevotella-dominant subjects had higher circulating levels of LPS and a lower abundance of pathways encoding butyrate production.

What are the greatest implications of this study?

Our findings suggest that a Prevotella copri dominant bacterial community is associated with a greater risk for NAFLD disease progression, probably linked to higher intestinal permeability and lower capacity for butyrate production.

What was studied?

This study investigated the duodenal mucosa-associated microbiota and its surrounding microenvironment in relation to hyperglycemia, an area far less studied than stool microbiota in metabolic disease. The researchers compared paired stool and duodenal microbial samples between hyperglycemic and normoglycemic individuals. They also assessed the duodenal microenvironment directly by measuring tissue oxygen saturation, serum inflammatory markers, and zonulin as a marker of gut permeability. The goal was to determine whether duodenal, rather than stool, microbial changes track more closely with glycemic status.

Who was studied?

The study population consisted of 33 subjects with hyperglycemia, defined as HbA1c of 5.7% or higher and fasting plasma glucose above 100 mg/dl, compared against 21 normoglycemic subjects. Both groups contributed paired stool and duodenal samples, allowing direct comparison of microbiota across two body sites within the same individuals. No further demographic details are given in the abstract.

What were the most important findings?

Hyperglycemic subjects had a significantly higher duodenal bacterial count than normoglycemic subjects, along with increased pathobionts and reduced beneficial flora. This bacterial overload correlated with elevated serum zonulin and higher TNF-alpha, suggesting a link to increased gut permeability and inflammation. The hyperglycemic group also showed reduced duodenal oxygen saturation, higher total leukocyte count, and lower IL-10, indicating a systemic proinflammatory state. Notably, unlike stool flora, duodenal bacterial profile variability was specifically associated with glycemic status.

What are the greatest implications of this study?

These findings suggest the duodenal microbiome and its local microenvironment, rather than stool alone, may play a distinct role in the pathogenesis of hyperglycemia and prediabetes. The association between bacterial overload, reduced oxygen saturation, and systemic inflammatory markers points to a possible mechanistic pathway linking small intestinal dysbiosis to metabolic dysfunction. This work highlights the duodenum as an underexplored but potentially important site for understanding and possibly intervening in early glycemic disturbances.

What was studied?

This study examined how the gut microbiota changes with age and how those age-related changes relate to colorectal cancer (CRC). The researchers analyzed 11 metagenomic data sets, correcting for batch effects, then compared species composition and abundance across three age groups in both healthy individuals and CRC samples. They used LEfSe analysis to identify bacteria whose relative abundance differed by age group, then built age-prediction and CRC-risk-prediction models from those age-differentiated species.

Who was studied?

The abstract does not report a single original cohort with a specific sample size. Instead, the study population consisted of previously published metagenomic samples drawn from 11 combined data sets accessed through the curatedMetagenomicData R package, covering both healthy individuals and people with colorectal cancer. These samples were stratified into three age groups for comparison.

What were the most important findings?

The structure and composition of the gut microbiota differed significantly across the three age groups in both healthy and CRC samples. Bacteroides vulgatus abundance was lower in the older group compared to the other two groups, while Bacteroides fragilis abundance increased with aging. The researchers also identified seven bacterial species whose abundance rose with age, and found that abundance of pathogenic bacteria, including Escherichia coli, increased as well.

What are the greatest implications of this study?

By linking specific age-associated shifts in gut microbiota, such as declining Bacteroides vulgatus and rising Bacteroides fragilis and Escherichia coli, to both healthy aging and CRC samples, this work suggests the microbiome could serve as a biomarker for biological aging and CRC risk. The construction of age-prediction and CRC-risk-prediction models based on these age-differentiated bacteria points toward potential microbiota-based tools for estimating cancer risk as people age. This approach could inform future screening or risk-stratification strategies that account for age-related microbial changes.

What was studied?

Children of mothers with gestational diabetes mellitus (GDM) are more prone to acquire type 2 diabetes and obesity as adults. Due to this link, early intervention strategies that alter the gut microbiome may benefit the mother and kid long-term. This work uses metagenomic and transcriptome sequencing to investigate how probiotics affect gut microbiota dysbiosis and inflammation in GDM.

Who was studied?

GDM and control metagenomic sequencing data were obtained from the SRA database. This metagenomic data helped us understand gut microbiota abundance and function. KEGG detected and extracted functional pathway genes. Transcriptome sequencing data evaluated GDM-related gene expression. Finally, GDM animal models were given probiotics orally to evaluate inflammatory response, regulatory immune cell fractions, and leptin protein levels.

What were the most important findings?

GDM patients had more Fusobacteria and Firmicutes, while healthy people had more Bacteroidetes. Gut microbiota composition may affect GDM by altering the L-aspartate and L-asparagine super pathways. Mannan degradation and the super pathway of L-aspartate and L-asparagine synthesis enhanced in GDM mice with leptin protein overexpression. Oral probiotics prevent GDM by lowering leptin. Oral probiotics increased Treg, Tfr, and Breg cells, which decreased TNF-α and IL-6 and increased TGF-β and IL-10, preventing inflammation and preserving mouse pregnancy.

What are the greatest implications of this study?

Dysbiosis of the gut microbiota may increase leptin expression and cause GDM. Oral probiotics enhance Treg, Tfr, and Breg cells, which limit the inflammatory response and assist mice in sustaining normal pregnancy. Thus, oral probiotics may prevent GDM, enabling targeted gut microbiota modulation and maternal and fetal health.

What was studied?

This study used metagenomic sequencing to characterize the gut microbiota of patients with non-segmental vitiligo. Researchers examined microbial community composition, diversity, and gene functions using bioinformatic analysis. They also predicted gut metabolic modules with the KEGG and MetaCyc databases to identify functional differences linked to the disease.

Who was studied?

The study enrolled 25 patients with non-segmental vitiligo and 25 matched healthy controls. All 50 participants underwent metagenomic sequencing of their gut microbiota for comparison between the two groups.

What were the most important findings?

Alpha diversity of the gut microbiome was significantly reduced in vitiligo patients compared with healthy controls. At the species level, Staphylococcus thermophiles was decreased while Bacteroides fragilis was increased in patients with vitiligo. LEfSe analysis identified additional microbial markers distinguishing vitiligo patients, including Lachnospiraceae_bacterium_BX3, Massilioclostridium_coli, and TM7_phylum_sp_oral_taxon_348, alongside Bacteroides_fragilis.

What are the greatest implications of this study?

These findings support a link between altered gut microbial composition and non-segmental vitiligo, reinforcing gut dysbiosis as a feature of the disease. The reduced diversity and specific species shifts, particularly the increase in Bacteroides fragilis, may serve as microbial markers for further investigation. Characterizing associated gene functions and metabolic modules could help clarify mechanisms connecting gut microbiota to vitiligo pathogenesis.

What was studied?

Chemoradiation (CRT) in patients with locally advanced head and neck squamous cell cancer (HNSCC) is associated with significant toxicities, including mucositis. The gut microbiome represents an emerging hallmark of cancer and a potentially important biomarker for CRT-related adverse events. This prospective study investigated the association between the gut microbiome composition and CRT-related toxicities in patients with HNSCC, including mucositis.

Who was studied?

Stool samples from patients diagnosed with locally advanced HNSCC were prospectively collected prior to CRT initiation and analyzed using shotgun metagenomic sequencing to evaluate gut microbiome composition at baseline. Concurrently, clinicopathologic data, survival outcomes and the incidence and grading of CRT-emergent adverse events were documented in all patients.

What were the most important findings?

A total of 52 patients were included, of whom 47 had baseline stool samples available for metagenomic analysis. Median age was 62, 83 % patients were men and 54 % had stage III-IV disease. All patients developed CRT-induced mucositis, including 42 % with severe events (i.e. CTCAE v5.0 grade ≥ 3) and 25 % who required enteral feeding. With a median follow-up of 26.5 months, patients with severe mucositis had shorter overall survival (HR = 3.3, 95 %CI 1.0-10.6; p = 0.02) and numerically shorter progression-free survival (HR = 2.8, 95 %CI, 0.8-9.6; p = 0.09). The gut microbiome beta-diversity of patients with severe mucositis differed from patients with grades 1-2 mucositis (p = 0.04), with enrichment in Mediterraneibacter (Ruminococcus gnavus) and Clostridiaceae family members, including Hungatella hathewayi. Grade 1-2 mucositis was associated with enrichment in Eubacterium rectale, Alistipes putredinis and Ruminococcaceae family members. Similar bacterial profiles were observed in patients who required enteral feeding.

What are the greatest implications of this study?

Patients who developed severe mucositis had decreased survival and enrichment in specific bacteria associated with mucosal inflammation. Interestingly, these same bacteria have been linked to immune checkpoint inhibitor resistance.

What was studied?

We aim to evaluate the differences in the microbiome of responders and non-responders, as well as predict the response to probiotic therapy, based on fecal microbiome data in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Who was studied?

A multi-strain probiotics that contains Lactobacillus acidophilus (KCTC 11906BP), Lactobacillus plantarum (KCTC11867BP), Lactobacillus rhamnosus (KCTC 11868BP), Bifidobacterium breve (KCTC 11858BP), Bifidobacterium lactis (KCTC 11903BP), Bifidobacterium longum (KCTC 11860BP), and Streptococcus thermophilus (KCTC 11870BP) were used. Patients were categorized into probiotic and placebo groups, and fecal samples were collected from all patients before and at the end of 8 weeks of treatment. The probiotic group was further divided into responders and non-responders. Responders were defined as patients who experienced adequate relief of overall irritable bowel syndrome symptoms after probiotic therapy. Fecal microbiota were investigated using Illumina MiSeq and analyzed using the EzBioCloud 16S database and microbiome pipeline (https://www.EZbiocloud.net).

What were the most important findings?

There was no significant difference in the alpha and beta diversity between the responder and non-responder groups. The abundances of the phylum Proteobacteria and genus Bacteroides significantly decreased after probiotic treatment. Bifidobacterium bifidum, Pediococcus acidilactici, and Enterococcus faecium showed a significantly higher abundance in the probiotic group after treatment compared to the placebo group. Enterococcus faecalis and Lactococcus lactis were identified as biomarkers of non-response to probiotics. The abundance of Fusicatenibacter saccharivorans significantly increased in the responders after treatment.

What are the greatest implications of this study?

Probiotic treatment changes some composition of fecal bacteria in patients with IBS-D. E. faecalis and L. lactis may be prediction biomarkers for non-response to probiotics. Increased abundance of F. sccharivorans is correlated to symptom improvement by probiotics in patients with IBS-D.

What was studied?

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and adolescents. The gut microbiota plays an important role in the pathophysiology of NAFLD through the gut-liver axis. Therefore, we aimed to investigate the genus and species of gut microbiota and their functions in children and adolescents with NAFLD. From May 2017 to July 2018, a total of 58 children and adolescents, including 27 abnormal weight (AW) (obese) NAFLD patients, 16 AW non-NAFLD children, and 15 healthy children, were enrolled in this study at Shenzhen Children's Hospital. All of them underwent magnetic resonance spectroscopy (MRS) to quantify the liver fat fraction. Stool samples were collected and analysed with metagenomics. According to body mass index (BMI) and MRS proton density fat fraction (MRS-PDFF), we divided the participants into BMI groups, including the AW group (n = 43) and the Lean group (n = 15); MRS groups, including the NAFLD group (n = 27) and the Control group (n = 31); and BMI-MRS 3 groups, including NAFLD_AW (AW children with NAFLD) (n = 27), Ctrl_AW (n = 16) (AW children without NAFLD) and Ctrl_Lean (n = 15). There was no difference in sex or age among those groups (p > 0.05). In the BMI groups, at the genus level, Dialister, Akkermansia, Odoribacter, and Alistipes exhibited a significant decrease in AW children compared with the Lean group. At the species level, Megamonas hypermegale was increased in the AW group, while Akkermansia muciniphila, Dialister invisus, Alistipes putredinis, Bacteroides massiliensis, Odoribacter splanchnicus, and Bacteroides thetaiotaomicron were decreased in AW children, compared to the Lean group. Compared with the Control group, the genus Megamonas, the species of Megamonas hypermegale and Megamonas rupellensis, increased in the NAFLD group. Furthermore, the genus Megamonas was enriched in the NAFLD_AW group, while Odoribacter, Alistipes, Dialister, and Akkermansia were depleted compared with the Ctrl_Lean or Ctrl_AW group at the genus level. Megamonas hypermegale and Megamonas rupellensis exhibited a significant increase in NAFLD_AW children compared with the Ctrl_Lean or Ctrl_AW group at the species level. Compared with healthy children, the pathways of P461-PWY contributed by the genus Megamonas were significantly increased in NAFLD_AW. We found that compared to healthy children, the genus Megamonas was enriched, while Megamonas hypermegale and Megamonas rupellensis were enriched at the species level in children and adolescents with NAFLD. This indicates that the NAFLD status and/or diet associated with NAFLD patients might lead to the enrichment of the genus Megamonas or Megamonas species.

What was studied?

This study examined the gut microbial composition and structure associated with colorectal cancer (CRC) across populations from different geographic regions. Researchers used whole-genome sequencing (WGS) data, annotated with MetaPhlAn2, to determine species and genus level relative abundance. They applied PCA and LEfSe analysis to compare microbial differences between regional datasets and used Spearman correlation analysis to examine relationships among CRC-associated differential species. The ultimate goal was to build and verify CRC risk prediction models based on these regional microbial differences.

Who was studied?

The analysis drew on a metagenomic dataset of 601 samples collected from six countries, sourced from the GMrepo and NCBI databases. This represents a secondary analysis of previously generated whole-genome sequencing data rather than a newly recruited clinical cohort. The abstract does not specify individual patient demographics such as age or sex, only the multi-country, multi-sample composition of the dataset.

What were the most important findings?

The composition of the intestinal bacterial community varied by region, and the specific differential intestinal bacteria linked to CRC were inconsistent from country to country. Despite this regional variability, the researchers identified a common diversity of bacteria shared across all six countries, including Peptostreptococcus. These findings indicate that CRC-associated microbiota show both a conserved core signature and considerable geographic variation.

What are the greatest implications of this study?

The findings suggest that CRC risk prediction models based on gut microbiota may need to account for regional differences in microbial composition rather than assuming a universal signature. Identifying bacteria that are consistently associated with CRC across diverse populations, such as Peptostreptococcus, could support more broadly generalizable diagnostic or risk-assessment tools. At the same time, the region-specific differences highlight the importance of validating any microbiome-based CRC model within the population it will be applied to.

What was studied?

This study examined whether gut microbiome composition is linked to disease severity in patients with COVID-19, and whether any microbiome disturbances resolve after the SARS-CoV-2 virus is cleared. Researchers used shotgun sequencing of total DNA extracted from stool samples to characterize gut microbiome composition. They also measured concentrations of inflammatory cytokines and other blood markers from plasma to relate gut microbial changes to immune dysfunction.

Who was studied?

The study drew on a two-hospital cohort of 100 patients with laboratory-confirmed SARS-CoV-2 infection, from whom blood, stool, and patient records were collected. Serial stool samples were collected from 27 of these 100 patients for up to 30 days after clearance of the virus, allowing the researchers to track whether microbiome changes persisted or resolved over time.

What were the most important findings?

Gut microbiome composition was significantly altered in patients with COVID-19 compared with non-COVID-19 individuals, regardless of whether patients had received medication. Several gut commensals with known immunomodulatory potential, including Faecalibacterium prausnitzii, Eubacterium rectale, and bifidobacteria, were underrepresented in patients with COVID-19. These organisms remained depleted in stool samples collected up to 30 days after disease resolution, indicating the perturbation did not quickly correct itself.

What are the greatest implications of this study?

The persistence of a disturbed gut microbiome for weeks after viral clearance suggests COVID-19 related gut dysbiosis is not merely a transient bystander effect of infection. Because the depleted organisms, including Faecalibacterium prausnitzii, are known for anti-inflammatory and immunomodulatory functions, their loss may contribute to dysfunctional immune responses seen in the disease. This points to the gut microbiome as a potential factor in COVID-19 severity and recovery, meriting further investigation as a target for monitoring or intervention.

What was studied?

This study examined the gut microbiota of patients with COVID-19 pneumonia using 16S rRNA gene sequencing performed on rectal swabs. Researchers compared microbial composition and diversity between patients treated in the intensive care unit (i-COVID19), patients treated in infectious disease wards (w-COVID19), and healthy controls (CTRL). The goal was to characterize how gut microbial communities differ across varying levels of COVID-19 disease severity.

Who was studied?

The study population consisted of patients hospitalized with COVID-19 pneumonia, divided into two groups by care setting: those admitted to the intensive care unit and those managed in infectious disease wards. These two patient groups were compared against a control group without COVID-19. The abstract does not report exact sample sizes, ages, or other demographic details for these cohorts.

What were the most important findings?

Patients in the ICU showed a decrease in the Chao1 index compared to both controls and ward patients, indicating lower microbial richness in the most severely ill patients, while the Shannon index showed no significant change. At the phylum level, ward patients showed an increase in Proteobacteria compared to controls. Fusobacteria and Spirochetes were both decreased relative to controls, with Spirochetes showing the greatest decrease in ICU patients specifically.

What are the greatest implications of this study?

The findings indicate that gut microbial communities shift in composition and richness according to COVID-19 disease severity, with the most pronounced changes occurring in critically ill ICU patients. These preliminary results suggest the gut microbiota may hold promising biomarkers for diagnosing COVID-19 and gauging disease severity. The authors note that validation in larger cohorts could support using microbiota profiles to help stratify patients by severity.

What was studied?

Gut transit time is a key modulator of host-microbiome interactions, yet this is often overlooked, partly because reliable methods are typically expensive or burdensome. The aim of this single-arm, single-blinded intervention study is to assess (1) the relationship between gut transit time and the human gut microbiome, and (2) the utility of the 'blue dye' method as an inexpensive and scalable technique to measure transit time.

Who was studied?

We assessed interactions between the taxonomic and functional potential profiles of the gut microbiome (profiled via shotgun metagenomic sequencing), gut transit time (measured via the blue dye method), cardiometabolic health and diet in 863 healthy individuals from the PREDICT 1 study.

What were the most important findings?

We found that gut microbiome taxonomic composition can accurately discriminate between gut transit time classes (0.82 area under the receiver operating characteristic curve) and longer gut transit time is linked with specific microbial species such as Akkermansia muciniphila, Bacteroides spp and Alistipes spp (false discovery rate-adjusted p values <0.01). The blue dye measure of gut transit time had the strongest association with the gut microbiome over typical transit time proxies such as stool consistency and frequency.

What are the greatest implications of this study?

Gut transit time, measured via the blue dye method, is a more informative marker of gut microbiome function than traditional measures of stool consistency and frequency. The blue dye method can be applied in large-scale epidemiological studies to advance diet-microbiome-health research. Clinical trial registry website https://clinicaltrials.gov/ct2/show/NCT03479866 and trial number NCT03479866.

What was studied?

This study examined changes in intestinal bacterial communities across healthy people, patients with inflammatory bowel disease (IBD), and patients with colorectal cancer (CRC). The researchers performed metagenome-wide association studies on fecal samples to characterize bacterial community structure, relative abundance, and functional predictions. They also analyzed differentially abundant bacteria and co-occurrence networks to compare the three groups.

Who was studied?

The analysis drew on fecal metagenomic data from 290 healthy subjects, 512 IBD patients, and 285 CRC patients. Healthy and CRC data were obtained from the European Nucleotide Archive under several study accession numbers, while IBD patient data came from the Integrated Human Microbiome Project via the Human Microbiome Project Data Portal. This makes the cohort a large, multi-source pooled metagenomic dataset rather than a single newly recruited study population.

What were the most important findings?

The bacterial community structure in both IBD and CRC patients differed significantly from that of healthy subjects. Notably, IBD patients showed low intestinal bacterial diversity, while CRC patients showed high intestinal bacterial diversity, a contrasting pattern between the two disease states. The abstract does not specify Faecalibacterium prausnitzii, butyrate, or other named commensals, so no claim is made about those organisms here.

What are the greatest implications of this study?

The finding that IBD and CRC involve opposite directions of diversity change suggests these two diseases are associated with distinct, rather than uniform, disruptions of the gut microbiome. This distinction could help refine how metagenomic diversity and community structure are used to distinguish disease states from health and from each other. It also underscores the value of large, pooled public metagenomic datasets for characterizing disease-associated microbial signatures.

What was studied?

This study examined the fecal gut metagenomes of three common intestinal diseases: Crohn's disease, ulcerative colitis, and colorectal cancer. The researchers performed a meta-analysis across 13 separate fecal metagenome data sets spanning these three conditions. Their goal was to identify microbial species and metabolic pathways that change consistently across multiple data sets for each disease, and to compare these signatures across diseases. They also built multidisease diagnostic models based on the markers they identified.

Who was studied?

The abstract does not describe a single new patient cohort but rather a meta-analysis pooling 13 existing fecal metagenome data sets covering Crohn's disease, ulcerative colitis, and colorectal cancer patients and controls. No specific sample sizes, ages, or geographic origins are given in the abstract. This can be honestly described as a secondary analysis of multiple public or previously published metagenomic cohorts rather than a single primary study population.

What were the most important findings?

The analysis identified 87 marker species and 65 marker pathways that were consistently altered across multiple data sets of the same disease. These markers grouped into disease-specific and disease-common clusters with distinct phylogenetic relationships: species specific to Crohn's disease were phylogenetically closely related, while colorectal cancer-specific species were more phylogenetically distant from one another. Notably, ulcerative colitis-specific species were phylogenetically closer to colorectal cancer-associated species, consistent with the known elevated colorectal cancer risk in ulcerative colitis patients. Marker species within the same cluster shared metabolic preferences, and disease cases showed more tightly coordinated microbial changes than controls, suggesting a more stressed, selective gut environment in disease states, with a subset of markers also correlating with an indicator of gut barrier (leaky gut) dysfunction.

What are the greatest implications of this study?

By mapping how disease-specific and disease-common microbial signatures relate phylogenetically and metabolically, this work supports the development of multidisease diagnostic models that could help distinguish between conditions with overlapping symptoms, such as Crohn's disease, ulcerative colitis, and colorectal cancer. The finding that ulcerative colitis markers resemble colorectal cancer markers phylogenetically offers a microbiome-based rationale for the elevated cancer risk seen in ulcerative colitis. The link between marker species and leaky gut indicators further ties gut dysbiosis to compromised intestinal barrier function. Overall, the study suggests cross-disease microbiome comparisons can sharpen diagnostic precision beyond single-disease marker panels.

What was studied?

This study examined whether the intestinal microbiome influences clinical outcome and treatment side effects in early breast cancer. Researchers used shotgun metagenomics to characterize fecal microbiota composition and paired this with plasma metabolomics. They looked at associations between the gut microbiota, measured at baseline and after chemotherapy, and both breast cancer prognosis and therapy-induced side effects. Findings were then tested for clinical relevance in an immunocompetent mouse model colonized with patient microbiota and challenged with mouse breast cancer and chemotherapy.

Who was studied?

The human cohort consisted of 76 early breast cancer patients contributing 121 fecal specimens, with 45 patients providing paired samples collected before and after chemotherapy. These patients were enrolled in the CANTO prospective study, which was designed to record side effects associated with clinical management of breast cancer. The findings were further validated in immunocompetent mice colonized with breast cancer patient microbiota.

What were the most important findings?

Specific gut commensals were found to be overabundant in breast cancer patients compared with healthy individuals. These overabundant commensals were associated with worse breast cancer prognosis. Chemotherapy modulated the abundance of these gut microbes, and the same microbes appeared to influence weight gain and neurological side effects linked to breast cancer therapies.

What are the greatest implications of this study?

The results suggest that gut microbiota composition could serve as a modifiable factor affecting both cancer prognosis and treatment tolerability in early breast cancer. Because chemotherapy itself reshapes these microbial communities, monitoring or targeting the microbiome during treatment may offer a way to improve outcomes and reduce side effects. The authors note that these findings, obtained in adjuvant and neoadjuvant settings, warrant prospective validation before any clinical application.

What was studied?

This study examined whether an ileal bile acid transporter inhibitor (IBATi), a drug developed to treat chronic idiopathic constipation, could improve nonalcoholic fatty liver disease (NAFLD) by acting on the gut microbiota. IBATi increases delivery of bile acids to the colon, and the researchers tested whether this shift in colonic bile acid exposure could alter gut bacteria in a way that benefits the liver. They measured body weight, liver function markers, serum lipids, NAFLD activity scores, and expression of bile-acid-related genes (Cyp7a1 in liver, Fgf15 in ileum) in high-fat diet (HFD) mice treated with IBATi.

Who was studied?

The subjects were mice fed a high-fat diet to induce a NAFLD model, with some receiving IBATi treatment alongside the HFD. Gut microbiota composition was assessed from fecal samples using 16S rRNA sequencing. A separate cohort of antibiotic-treated mice was recolonized through fecal microbiome transplantation (FMT) using stool from either HFD or HFD-plus-IBATi donor mice, allowing the researchers to test whether the microbiota itself could transfer the treatment effect.

What were the most important findings?

IBATi treatment significantly suppressed body weight gain, improved liver dysfunction, lowered serum LDL levels, and reduced NAFLD activity scores compared to untreated HFD mice. It also reversed HFD-induced decreases in hepatic Cyp7a1 and increased ileal Fgf15 expression, both markers of altered bile acid signaling. IBATi changed gut microbiota alpha-diversity that had been reduced by the high-fat diet, and this altered microbiota profile was able to be transferred to antibiotic-treated recipient mice via fecal transplantation.

What are the greatest implications of this study?

The findings suggest that redirecting bile acids to the colon with an ileal bile acid transporter inhibitor can improve hepatic steatosis largely through correction of gut microbiota dysbiosis, rather than through direct liver-only mechanisms. Because the FMT experiments show the microbiota changes themselves reproduce benefits, this supports the gut-liver axis as a therapeutic target for NAFLD. This positions IBATi, an already-used constipation drug, as a potential repurposed candidate for NAFLD treatment pending further research.

What was studied?

This study examined the composition of gut microbiota in people with obesity compared to control subjects using 16S rRNA sequencing of fecal bacteria. The researchers analyzed differences in microbial diversity and abundance at multiple taxonomic levels, including the phylum level. They also used bioinformatics and statistical methods to predict functional potential changes in the microbiota associated with obesity.

Who was studied?

The study compared 21 adults with obesity to 21 control subjects. The obesity group's fecal samples were sequenced on an Illumina MiSeq instrument, while the control group's raw sequencing data came from 21 healthy Beijing volunteers downloaded from the Microbial Genome Database System. Both groups therefore consisted of 21 individuals each, drawn from comparable population sources.

What were the most important findings?

Gut microbiota diversity decreased significantly in people with obesity compared to controls. Significant differences between the two groups were found at multiple levels, including notable shifts in the phyla Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria. Notably, the ratio of Firmicutes to Bacteroidetes decreased significantly in the obesity group, a reversal of the pattern often reported in prior obesity microbiome research.

What are the greatest implications of this study?

These findings reinforce that gut microbiota composition and diversity are meaningfully altered in obesity, supporting the idea that the microbiome plays a role in this condition. The observed shift in the Firmicutes/Bacteroidetes ratio and changes in functional potential suggest that microbiota profiling could help characterize metabolic differences in people with obesity. This work adds to the evidence base motivating further investigation into gut bacteria as a factor in obesity and its associated health burden.

What was studied?

This study examined the composition of the gut microbiome in patients with Parkinson's disease (PD) using shotgun metagenomic sequencing. Researchers compared the fecal microbial profiles of PD patients against those of healthy control subjects. The analysis included taxonomic composition as well as functional gene-category profiling using the Cluster of Orthologous Groups, KEGG Orthology, and carbohydrate-active enzyme databases. A random forest model was also built to test whether microbiome features could distinguish PD patients from controls.

Who was studied?

The cohort consisted of 39 patients with Parkinson's disease (the PD group) recruited in central China. The comparison group was made up of the corresponding 39 healthy spouses of these patients (the SP group), who served as controls. Using spouses as controls is notable because it helps account for shared household diet and environment.

What were the most important findings?

Gut microbial composition was significantly altered in PD patients compared to healthy spouses. A key novel finding was enrichment of Bilophila wadsworthia in the gut microbiome of PD patients, which had not been reported in prior studies. The random forest model reliably discriminated PD patients from controls, achieving an area under the receiver operating characteristic curve of 0.803. Klebsiella and Parasutterella abundances were positively correlated with PD duration and severity, while hydrogen-generating Prevotella was negatively correlated with disease severity, and functional analyses pointed to altered branched-chain amino acid-related proteins.

What are the greatest implications of this study?

The enrichment of Bilophila wadsworthia, a sulfate-reducing, hydrogen sulfide-producing organism, suggests that sulfur metabolism in the gut may play a previously unrecognized role in PD pathophysiology. The strong discriminative performance of the microbiome-based model suggests gut microbial signatures could eventually support non-invasive screening or monitoring of PD. Correlations between specific taxa and disease duration or severity suggest the microbiome may track with clinical progression rather than being a static marker. These findings support further investigation into gut bacteria, including hydrogen and sulfide-related metabolism, as contributors to PD development or severity.

What was studied?

This study examined the relationship between the gut microbiota and psychiatric symptom severity among inpatients with serious mental illness. Researchers used 16S rRNA gene sequencing and whole genome shotgun sequencing to characterize fecal samples collected early in hospitalization. They then tested whether microbial richness and alpha diversity were associated with depression, anxiety, trauma, and suicide severity measures, and whether these microbial features predicted treatment outcome at discharge.

Who was studied?

The study population consisted of 111 adult inpatients with serious mental illness. Diagnoses, suicide severity, trauma, depression, and anxiety were assessed shortly after admission. Participants self-collected fecal swabs early in the course of their hospital stay for microbiota analysis.

What were the most important findings?

Depression and anxiety severity shortly after admission were negatively associated with bacterial richness and alpha diversity, meaning more severe symptoms corresponded to a less rich and less diverse gut microbiota. Specific bacterial taxa were identified as associated with depression and anxiety severity. Gut microbiota richness and alpha diversity measured early in hospitalization also significantly predicted depression remission by the time of discharge.

What are the greatest implications of this study?

The findings support a link between gut microbial diversity and psychiatric symptom severity in a clinical inpatient population, extending prior evidence from animal models and small human studies. Because early microbiota measures predicted depression remission at discharge, gut microbiota composition may hold value as a marker of treatment response in serious mental illness. This strengthens the rationale for further investigating the brain-gut relationship as a factor in psychiatric care and outcomes.

Who was studied?

Thirty-seven patients with advanced NSCLC receiving treatment with nivolumab were enrolled in CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491). Fecal samples were collected at the starting point, when patients received nivolumab, at clinical evaluation, and when disease progression was noted. 16S ribosome RNA gene sequencing was applied to assess gut microbiota profiles. Peripheral immune signatures were determined by multicolor flow cytometry in parallel.

What were the most important findings?

When subgrouping patients into responder (R) and nonresponder according to the clinical response assessed using Response Evaluation Criteria in Solid Tumor version 1.1, R patients harbored higher diversity of gut microbiome at the starting point with stable composition during the treatment. Patients with high microbiome diversity had significantly prolonged progression-free survival when compared to those with low diversity. Compositional difference was observed between the two groups as well with the enrichment of Alistipes putredinis, Bifidobacterium longum, and Prevotella copri in R whereas Ruminococcus_unclassified enriched in nonresponding patients. Analysis of systemic immune responses using multicolor flow cytometry revealed that patients with a high abundance of microbiome diversity in the gut had a greater frequency of unique memory CD8+ T cell and natural killer cell subsets in the periphery in response to anti-PD-1 therapy.

What are the greatest implications of this study?

Our results reveal strong correlation between gut microbiome diversity and the responses to anti-PD-1 immunotherapy in Chinese patients with advanced NSCLC. Patients with favorable gut microbiome (such as those with high diversity) exhibit enhanced memory T cell and natural killer cell signatures in the periphery. These findings provide important implications for the prediction and the evaluation of anti-PD-1 immunotherapy against NSCLC in the Chinese population.

What was studied?

This study investigated the gut microbiome and metabolome in colorectal cancer (CRC) to test whether host-microbiome associations found in prior research, mostly from developed countries, also hold in a distinct population. Researchers performed metagenomic and metabolomic analyses of fecal samples, then compared their results with CRC microbiome data available from other populations. The focus was on identifying bacterial taxa and metabolic pathways linked to CRC in a setting where the disease has historically been rare.

Who was studied?

The study analyzed fecal samples from 30 colorectal cancer patients and 30 healthy controls recruited from two different locations in India. This population was chosen specifically because India has a low incidence of colorectal cancer and a distinct diet, lifestyle, and gut microbiome compared to other global populations. Data from this Indian cohort were also compared against previously published CRC microbiome datasets from other countries.

What were the most important findings?

The researchers confirmed that Bacteroides and other bacterial taxa already linked to CRC in earlier studies were also associated with CRC in this Indian cohort. A novel finding was the association of Flavonifractor plautii, a flavonoid-degrading bacterium, with CRC in these patients. This association correlated with enzymes and metabolic modules involved in flavonoid degradation, suggesting a link between the breakdown of beneficial anticarcinogenic flavonoids and the disease. The team also identified 20 potential microbial taxonomic markers and 33 potential microbial gene markers that distinguished CRC from healthy microbiomes with high accuracy using machine learning.

What are the greatest implications of this study?

The findings suggest that loss of beneficial, flavonoid-degrading control (via F. plautii) may contribute to cancer progression in this Indian cohort, expanding the known microbial players beyond previously identified taxa like Bacteroides. Because India has unusually low CRC incidence alongside a distinct gut microbiome, these cohort-specific biomarkers may not generalize globally and highlight the need for population-specific microbiome research. The taxonomic and gene markers identified could also support development of noninvasive, microbiome-based diagnostic tools for CRC in diverse populations.

What was studied?

This study evaluated DAV132, a product designed to deliver activated charcoal to the late ileum, as a means of protecting the gut microbiome during antibiotic treatment. Researchers tested whether coadministering DAV132 with the fluoroquinolone antibiotic moxifloxacin could adsorb residual antibiotic in the gut and limit its disruption of the intestinal microbiota. The trial also assessed plasma drug levels and safety, and separately tested DAV132's ability to adsorb other antibiotics outside the body.

Who was studied?

The study enrolled 28 human volunteers who received a 5-day clinical regimen of moxifloxacin, split into two parallel groups, one receiving DAV132 alongside the antibiotic and one not. Two additional control groups of 8 volunteers each received either DAV132 alone or a nonactive substitute. All participants appear to be healthy volunteers rather than patients with an existing condition.

What were the most important findings?

Coadministration of DAV132 reduced free moxifloxacin concentrations in feces by 99%, while plasma drug levels were unaffected, indicating the effect was localized to the gut and did not interfere with systemic antibiotic action. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects who received DAV132 with moxifloxacin. No adverse effects were observed, and DAV132 also efficiently adsorbed a wide range of clinically relevant antibiotics in ex vivo testing.

What are the greatest implications of this study?

These findings suggest DAV132 could be a practical tool for protecting the gut microbiome during antibiotic therapy without reducing the antibiotic's systemic availability or efficacy. Because DAV132 adsorbed multiple other antibiotics ex vivo, this approach may generalize beyond moxifloxacin to broader clinical use. Preserving microbiota richness and composition during antibiotic courses could help mitigate the short-term and longer-term consequences of antibiotic-associated microbiome disruption.

What was studied?

Intestinal microbes have been shown to influence predisposition to atopic disease, including food allergy. The intestinal microbiome of food-allergic children may differ in significant ways from genetically similar non-allergic children and age-matched controls. The aim was to characterize fecal microbiomes to identify taxa that may influence the expression of food allergy.

Who was studied?

Stool samples were collected from children with IgE-mediated food allergies, siblings without food allergy, and non-allergic controls. Stool microbiome characterization was performed via next-generation sequencing (Illumina) of the V1V3 and V4 variable regions of the 16S rRNA gene. Bacterial diversity, evenness, richness, and relative abundance of the operational taxonomic units (OTUs) were evaluated using QIIME. ANOVA and Welch's t test were utilized to compare groups.

What were the most important findings?

Sixty-eight children were included: food-allergic (n = 22), non-food-allergic siblings (n = 25), and controls (n = 21). When comparing fecal microbial communities across groups, differences were noted in Rikenellaceae (P = .035), Actinomycetaceae (P = .043), and Pasteurellaceae (P = .018), and nine other distinct OTUs. Food-allergic subjects had enrichment for specific microbes within the Clostridia class and Firmicutes phylum (Oscillobacter valericigenes, Lachnoclostridium bolteae, Faecalibacterium sp.) compared to siblings and controls. Identification of Clostridium sp. OTUs revealed differences in specific Clostridia drive the separation of the allergic from the siblings and controls. Alistipes sp. were enriched in non-allergic siblings.

What are the greatest implications of this study?

Comparisons in the fecal microbiome of food-allergic children, siblings, and healthy children point to key differences in microbiome signatures, suggesting the role of both genetic and environmental contributors in the manifestation of food-allergic disease.

What was studied?

This study examined whether the gastrointestinal microbiome and peripheral immune signaling are associated with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Researchers combined rigorous clinical characterization with fecal bacterial metagenomics and plasma immune molecule analyses. They specifically looked at whether irritable bowel syndrome (IBS) co-morbidity and body mass index shaped bacterial composition and bacterial metabolic pathways.

Who was studied?

The study included 50 patients diagnosed with ME/CFS and 50 healthy controls. Controls were frequency-matched to patients for age, sex, race/ethnicity, geographic site, and season of sampling. This matched case-control design allowed comparisons of fecal and plasma profiles between the two groups.

What were the most important findings?

Topological analysis linked IBS co-morbidity, body mass index, fecal bacterial composition, and bacterial metabolic pathways, but found no such association with plasma immune molecules. IBS co-morbidity was the strongest factor separating topological networks based on bacterial profiles and metabolic pathways. Predictive selection models confirmed that ME/CFS subgroups defined by IBS status could be distinguished from controls with high accuracy, and the bacterial taxa predictive of ME/CFS with IBS differed from those predictive of ME/CFS without IBS.

What are the greatest implications of this study?

The findings suggest ME/CFS is not a single uniform condition but includes at least two microbiome-linked subgroups defined by IBS status. Fecal bacterial profiles and metabolic pathways, rather than circulating immune molecules, appear to track most closely with this clinical subdivision. This supports stratifying ME/CFS patients by gut comorbidity status when investigating mechanisms or designing future microbiome-targeted studies.

What was studied?

This study examined how the gut microbiome and circulating serum metabolites differ between lean and obese individuals. Researchers used a metagenome-wide association study paired with serum metabolomics profiling to identify obesity-associated gut microbial species and link them to changes in blood metabolites. They further tested a specific microbial species, Bacteroides thetaiotaomicron, in mice to determine its direct effect on body weight and fat accumulation. The study also examined whether bariatric surgery could reverse the microbial and metabolic changes seen in obesity.

Who was studied?

The human portion of the study involved a cohort of lean and obese, young, Chinese individuals, though the abstract does not specify exact sample size. A subset of these obese individuals also underwent bariatric surgery as a weight-loss intervention, with pre- and post-surgery comparisons used to assess reversal of obesity-associated changes. In addition to the human cohort, the researchers used a mouse model to test the functional effects of B. thetaiotaomicron administration via gavage.

What were the most important findings?

The abundance of Bacteroides thetaiotaomicron, a glutamate-fermenting commensal, was markedly decreased in obese individuals and was inversely correlated with serum glutamate concentration. In mice, gavage with B. thetaiotaomicron reduced plasma glutamate concentration and alleviated diet-induced body-weight gain and adiposity. Weight-loss intervention by bariatric surgery partially reversed these obesity-associated microbial and metabolic alterations, including restoring B. thetaiotaomicron abundance and lowering elevated serum glutamate.

What are the greatest implications of this study?

These findings identify a previously unknown link between a specific gut commensal, circulating amino acid levels, and obesity. The inverse relationship between B. thetaiotaomicron and serum glutamate, confirmed functionally in mice, suggests this microbe helps regulate host metabolism through glutamate fermentation. The results suggest it may be possible to intervene in obesity by directly targeting the gut microbiota, offering a potential mechanistic target for future metabolic therapies.

What was studied?

This study examined how the gut microbiome changes along the colorectal adenoma-carcinoma sequence, the stepwise progression from benign polyps to invasive cancer. Researchers used a metagenome-wide association study (MGWAS) on stool samples to catalogue microbial genes, strains, and functional pathways at each stage. The goal was to identify which gut microbes and functions are specifically enriched in adenoma versus carcinoma, since colorectal cancer often develops slowly from these precursor polyps and the microbiota is thought to play a direct role in that process.

Who was studied?

The comparison groups were stool samples from patients with advanced adenoma, patients with carcinoma, and healthy control subjects. The abstract does not report specific sample sizes, ages, or geographic origin of the cohort. Beyond identifying these three clinical groups, the analysis also incorporated dietary risk-factor data, specifically relative intake of red meat versus fruits and vegetables.

What were the most important findings?

The MGWAS revealed distinct sets of microbial genes, strains, and functions that were enriched in the adenoma group and in the carcinoma group compared with healthy subjects, indicating that the gut microbiome shifts in a stage-specific way along this disease sequence. A risk-factor analysis linked higher intake of red meat relative to fruits and vegetables with the outgrowth of bacteria that may help create a more hostile, pro-carcinogenic gut environment. The abstract does not name specific taxa such as Bilophila, Desulfovibrio, or sulfate-reducing bacteria, nor does it mention hydrogen sulfide, bile acids, or taurine.

What are the greatest implications of this study?

By mapping microbial changes across the adenoma-carcinoma sequence, the findings support the idea that stool-based microbiome signatures could serve as biomarkers for early, non-invasive detection of colorectal adenoma or carcinoma. The diet-microbiome link suggests that dietary patterns high in red meat relative to plant foods may promote a gut microbial environment conducive to disease progression, pointing to a modifiable risk factor. Together, these results suggest faecal microbiome profiling could inform both earlier diagnosis and future microbiome-targeted treatment strategies for colorectal cancer.

What was studied?

This study examined the gut mucosal microbiome across sequential stages of colorectal tumorigenesis, from adenoma to carcinoma. Researchers catalogued microbial communities in lesion tissue and in adjacent, seemingly normal mucosae to trace how dysbiosis develops as colorectal cancer (CRC) progresses. They used probabilistic partitioning of relative abundance profiles to identify recurring microbial community configurations, or metacommunities, associated with each stage. They also examined correlation and co-exclusion patterns among bacterial taxa to characterize how community structure changes over the course of disease.

Who was studied?

The analysis drew on human gut mucosal tissue from 47 paired samples of adenoma and adenoma-adjacent mucosae, and 52 paired samples of carcinoma and carcinoma-adjacent mucosae. An additional 61 healthy control samples were included for comparison. The findings were further checked against two previously published, independently collected data sets to confirm the alterations observed in the CRC-associated microbiome.

What were the most important findings?

A metacommunity dominated by members of the oral microbiome was primarily associated with colorectal cancer, distinguishing cancerous tissue from healthy and precancerous states. Paired-sample analysis revealed clear differences in microbial community configuration between lesions and their adjacent mucosae. Correlation analysis of bacterial taxa showed early signs of dysbiosis already present in adenoma, the precancerous stage, while co-exclusive relationships among taxa became more common as tissue progressed to carcinoma. These patterns were validated against two independent published data sets, supporting the consistency of the association.

What are the greatest implications of this study?

The findings suggest that a taxonomically defined microbial consortium, enriched in oral-associated bacteria, is implicated in the development of colorectal cancer. Because dysbiosis signals appear as early as the adenoma stage, gut mucosal microbiome profiling could support earlier detection of precancerous changes. The progressive shift toward co-exclusive taxa relationships from adenoma to carcinoma points to microbial community structure, not just individual species, as a marker of disease progression. Validation across independent data sets strengthens the case for using defined microbial consortia as reproducible biomarkers in colorectal carcinogenesis.

What was studied?

This study examined how diet shapes gut microbial composition by comparing the fecal microbiota of children eating different diets. Researchers used high-throughput 16S rDNA sequencing together with biochemical analyses to characterize bacterial community composition and short-chain fatty acid output. The design set a fiber-rich, agrarian-style diet against a modern European diet to test whether microbiota differ along with dietary pattern.

Who was studied?

The study compared fecal samples from European children (EU) with those from children living in a rural African village in Burkina Faso (BF). The BF children's diet was high in fiber content and described as similar to the diet of early human settlements around the birth of agriculture. Exact sample sizes are not given in the abstract, but the comparison was structured as two defined pediatric cohorts, one European and one rural Burkinabe.

What were the most important findings?

BF children showed significant enrichment in Bacteroidetes and depletion in Firmicutes compared to EU children (P < 0.001). BF children also had a unique abundance of Prevotella and Xylanibacter, genera known to carry genes for cellulose and xylan hydrolysis, which were completely absent in EU children. BF children produced significantly more short-chain fatty acids than EU children (P < 0.001). Enterobacteriaceae, specifically Shigella and Escherichia, were significantly underrepresented in BF children relative to EU children (P < 0.05).

What are the greatest implications of this study?

The findings support the idea that gut microbiota coevolved with a polysaccharide-rich diet, helping BF children extract more energy from fiber through bacterial fermentation to short-chain fatty acids. The reduced abundance of Enterobacteriaceae, including Shigella and Escherichia, in the high-fiber BF group suggests diet may also influence the balance between beneficial fiber-degrading bacteria and potentially pathogenic Enterobacteriaceae. Together these results indicate that dietary pattern is a major driver of gut microbial ecology in children, with possible downstream effects on metabolic energy harvest and gut colonization resistance.